ArticleOman journal of ophthalmology
Transepithelial photorefractive keratectomy enhancement for myopic regression.
Article in Oman journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUncorrected refractive errors are a major global public health concern, responsible for approximately 50% of visual impairments. Surgical options such as photorefractive keratectomy (PRK) and laser METHODOLOGY: Trans-PRK was performed in eyes with myopic regression after previous PRK or LASIK with a mean refractive spherical equivalent (SE) of - 1.92 diopter (D) ±0.96 (standard deviation). The mean preoperative logMAR uncorrected distance visual acuity (UDVA) was 0.59 ± 0.38. Postoperative evaluation included UDVA, SE, epithelial healing, and haze formation at 1 week, 2 months, and 6 months.
resultsThe study evaluated 26 eyes of 15 patients. At 6 months postoperatively, the proportion of eyes within ± 0.50 D and ± 1.00 D of the target refraction was 37.5% and 100%, respectively. After the enhancement, the percentage of eyes with Snellen UDVA of 20/20 or better was 80% at 6 months, while all of the eyes had a Snellen UDVA of 20/25 or better. The mean postoperative SE was - 1.01 ± 0.74, at 1 week, -0.61 ± 0.98 at 3 months, and - 0.38 ± 0.57 at 6 months. No significant complications were noted.
conclusionsThe results of this study indicate that Trans-PRK appears to be safe, effective, stable, and predictable procedure for the treatment of myopic regression after previous PRK or LASIK.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.